Sensei CEO converts Series B into 761,428 shares

Sensei Biotherapeutics, Inc. President and CEO Anand Kiran Parikh converted preferred shares received in a merger into common stock.

Rhea-AI Filing Summary

Sensei Biotherapeutics, Inc. President and CEO Anand Kiran Parikh converted preferred shares received in a merger into common stock. He acquired 761,428 shares of Common Stock through the conversion of 761.428 shares of Series B Preferred Stock, which are convertible into 1,000 common shares each with no expiration date. The Series B Preferred Stock had been issued as consideration when Faeth Holdings Therapeutics, Inc. common stock was converted into the right to receive these preferred shares at the closing of a multi‑step merger involving Faeth and its holding entities.

Insights

Equity compensation and insider-transactions analyst

CEO converts merger-related preferred stock into common shares, a non-cash structural change.

The reporting person, Sensei Biotherapeutics’ President and CEO Anand Kiran Parikh, converted 761.428 shares of Series B Preferred Stock into 761,428 shares of Common Stock. The filing describes this as a conversion of a derivative security, not an open-market purchase or sale.

The footnotes explain that each Series B share is convertible into 1,000 common shares with no expiration date, and that these preferred shares were issued as consideration in a merger involving Faeth Holdings Therapeutics, Inc. All 761.428 preferred shares shown here were converted, leaving no remaining Series B position in this filing.

This is effectively a structural step that turns merger-related preferred equity into common equity, with no cash changing hands. The transaction does not indicate discretionary buying or selling by the CEO, so its informational value for equity sentiment is limited and best viewed as administrative merger cleanup.

Insider Trade Summary

761.428 shares exercised/converted

Exercise 2 txns

Insider Parikh Anand Kiran

Role President and CEO

Type	Security	Shares	Price	Value
Conversion	Series B Preferred Stock	761.428	$0.00	$0.00
Conversion	Common Stock	761,428	$0.00	$0.00

Holdings After Transaction: Series B Preferred Stock — 0 contracts (Direct); Common Stock — 761,428 shares (Direct)

Footnotes (3)

1. F1. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date.
2. F2. Pursuant to February 17, 2026 Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Faeth Holdings Therapeutics, Inc. ("HoldCo") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo ("Faeth"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the "Merger").
3. F3. Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive 761.428 shares of the Issuer's Series B Preferred Stock.

Key Figures

Common shares acquired: 761,428 shares Series B Preferred converted: 761.428 shares Conversion ratio: 1,000 common shares per Series B share +3 more

6 metrics

Common shares acquired 761,428 shares Common Stock received via derivative conversion on June 15, 2026

Series B Preferred converted 761.428 shares Series B Preferred Stock converted into Common Stock

Conversion ratio 1,000 common shares per Series B share Set in Certificate of Designation; no expiration date

Transaction price per share $0.0000 Reported for both Common Stock and Series B Preferred in this conversion

Common shares held after transaction 761,428 shares Total Common Stock directly owned after conversion

Derivative exercises in filing 1 transaction, 761.428 shares Exercise/convert of derivative security per transactionSummary

Key Terms

Series B Preferred Stock, Certificate of Designation, Agreement and Plan of Merger, Merger, +1 more

5 terms

Series B Preferred Stock financial

"each share of Series B Preferred Stock is convertible into 1,000 shares"

Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.

Certificate of Designation regulatory

"conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations"

A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.

Agreement and Plan of Merger regulatory

"Pursuant to February 17, 2026 Agreement and Plan of Merger (the "Merger Agreement")"

An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.

Merger financial

"such mergers, the "Merger""

A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.

wholly owned subsidiary financial

"with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer"

A wholly owned subsidiary is a company whose entire ownership is held by another company (the parent), so the parent controls decisions, operations, and finances. Think of it as a fully controlled branch that runs as its own legal entity but whose results flow straight into the parent’s financial statements; investors watch these structures because they affect consolidated revenue, risk exposure, and how profits, liabilities, and cash flow are allocated across the corporate group.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Sensei Biotherapeutics (SNSE) CEO Anand Kiran Parikh report in this Form 4?

He reported converting 761.428 shares of Series B Preferred Stock into 761,428 shares of Common Stock. The transaction is classified as a conversion of a derivative security, not a market trade, so it reflects restructuring of his equity rather than new buying or selling activity.

How many Sensei Biotherapeutics (SNSE) common shares did the CEO receive through this conversion?

He received 761,428 shares of Common Stock. These came from converting 761.428 shares of Series B Preferred Stock, which carries a 1,000‑to‑1 conversion ratio into common shares as described in the Series B Certificate of Designation, with no expiration date on the conversion right.

What is the conversion ratio of Sensei Biotherapeutics’ Series B Preferred Stock into common stock?

Each share of Series B Preferred Stock is convertible into 1,000 shares of Common Stock. This ratio is set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock and the shares have no stated expiration date for the conversion right.

How is this Form 4 transaction related to the Faeth Therapeutics merger with Sensei Biotherapeutics (SNSE)?

The Series B Preferred Stock was issued as merger consideration in a multi‑step transaction involving Faeth Holdings Therapeutics, Inc. Upon closing, Faeth common stockholders received 761.428 Series B Preferred shares, which the CEO’s filing shows being converted into 761,428 Sensei common shares as part of that structure.

Did the Sensei Biotherapeutics CEO buy or sell shares on the open market in this Form 4?

No, the filing does not show any open‑market purchases or sales. It records a conversion of Series B Preferred Stock into Common Stock, classified as a derivative conversion. The transaction shares carry a zero dollar per‑share transaction price, indicating no cash consideration exchanged.

Does the CEO still hold any Series B Preferred Stock of Sensei Biotherapeutics after this transaction?

According to the reported figures, his Series B Preferred Stock holding associated with this transaction is reduced to zero. The derivative line for 761.428 Series B shares shows a post‑transaction balance of 0.0000, indicating that all those preferred shares were converted into common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:38 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parikh Anand Kiran

(Last) (First) (Middle)

C/O FAETH THERAPEUTICS, INC.

701 TILLERY STREET #12 #1010

(Street)

AUSTIN TEXAS 78702

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sensei Biotherapeutics, Inc. [ FTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		C		761,428(1)	A	(2)(3)	761,428	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Preferred Stock(1)	(2)(3)	06/15/2026		C			761.428	(2)(3)	(2)(3)	Common Stock	761,428(1)	(2)(3)	0	D

Explanation of Responses:

1. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date.

2. Pursuant to February 17, 2026 Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Faeth Holdings Therapeutics, Inc. ("HoldCo") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo ("Faeth"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the "Merger").

3. Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive 761.428 shares of the Issuer's Series B Preferred Stock.

	/s/ Josiah Craver, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)